



STOP MS IN ITS TRACKS RESTORE WHAT'S BEEN LOST END THE DISEASE FOREVER

There are more potential MS therapies in development today than at any other time in history, and a variety of therapies exist for those with relapsing forms of multiple sclerosis.

For some, these treatments reduce the number and severity of attacks and slow disease activity, but more must be done to stop disease progression for everyone affected by MS — including those with progressive forms.

People with MS want, and deserve, solutions. We must find ways to stop all disease activity and prevent further progression for those who already have MS.

As part of a unique and comprehensive approach to MS research, the Society is committed to stopping MS in its tracks. Here's how:

WE MUST BETTER UNDERSTAND THE ROLE THE IMMUNE SYSTEM PLAYS IN THE CAUSE OF MS AND IN ONGOING DISEASE ACTIVITY.

- Studies focusing on the mechanics of the immune system, and its cells such as T cells, B cells, and how nervous system tissues become the target of MS attacks
- Research focusing on immune molecules involved in launching attacks, and on natural molecules that can put a stop to them
- Studies exploring the genetic markers of MS, which may hold the key to understanding how the MS immune attacks are triggered and may provide new avenues for stopping the attacks

WE MUST PURSUE THE RESEARCH LEADING TOWARD CLINICAL TRIALS OF NEW THERAPIES TO STOP DAMAGE AND PROGRESSION OF DISABILITY.

- Studies focusing on detecting and measuring disease activity using advanced imaging techniques and new clinical assessments to enhance and speed clinical trials of therapies that can stop MS immune activity and protect against further injury
- Investments aimed at pre-clinical studies of new approaches to stopping immune attacks
- Clinical trials of new approaches including vitamin D supplements, the antioxidant lipoic acid, and repurposing drugs approved for other disorders

WE DROVE THE DEVELOPMENT OF "GOLD STANDARDS" FOR THE DESIGN OF MS CLINICAL TRIALS, OPENING A PATH FOR FDA APPROVALS

"I WILL HAVE THE ENERGY I NEED TO TAKE CARE OF MY KIDS TONIGHT."

OUR FUNDING LED TO THE IDENTIFICATION OF 4 TYPES OF MS LESION PATTERNS, CHANGING THE WAY RESEARCHERS VIEW MS



Martha, diagnosed in 1973



STOP MS IN ITS TRACKS

WE MUST ENSURE THAT WE UNDERSTAND HEALTH CARE ISSUES AND CAN GATHER DATA TO ADVOCATE FOR POLICIES THAT ENABLE EVERYONE WITH MS TO ACCESS QUALITY CARE AND TREATMENT.

- Studies focusing on standards and indicators of good MS medical care, on modeling medical costs, and on impediments to care faced by people with MS
- Investigations of issues such as long-term care, housing needs and caregiver issues

WE MUST UNDERSTAND THE MECHANISMS THAT CAUSE TISSUE INJURY AND THAT DRIVE DISEASE PROGRESSION.

- Studies exploring mechanisms that drive injury to the brain and spinal cord to expose new potential therapeutic targets along the injury pathways that may stop the damage
- Advanced imaging and laboratory studies seeking to define and track the full measure of MS disease activity, MS lesions, and atrophy in the brain and spinal cord
- Epidemiology studies of people with MS designed to identify factors that contribute to the risk of MS progression

Significant progress has been made, but more must be done, NOW.

TO HELP **STOP MS** IN ITS TRACKS,
PLEASE CONSIDER A GENEROUS GIFT.

*Your support will revolutionize care and treatment options,
bringing real solutions to everyone living with MS.*

nationalMSSociety.org

SOCIETY INITIATIVES CREATED THE TOOLS THAT HAVE ENABLED QUICKER MS DIAGNOSIS, REDUCING THE AGONIZING WAIT FOR COUNTLESS PEOPLE



NOW and No Opportunity Wasted utilized with permission from NOW, Inc., and in partnership with Phil Keoghan, tireless advocate and Champion for MS Research.



MS NOW

An MS Research Revolution

OUR SUPPORT OF EARLY STUDIES LED TO MOST OF THE DISEASE-MODIFYING THERAPIES FOR MS

“ I WON’T HAVE TO WORRY ABOUT WAKING UP WITH LESS TOMORROW.”

OUR RESEARCH INITIATIVE ON GENDER DIFFERENCES LED TO THE FIRST CLINICAL TRIALS OF SEX HORMONES TO TREAT MS



Jason, diagnosed in 2002